References

amfAR (Foundation for AIDS Research). 2019. Syringe exchange programs. https://opioid. amfar.org/indicator/num_SSPs (accessed September 13, 2019).

Andrews, C., A. Abraham, C. M. Grogan, H. A. Pollack, C. Bersamira, K. Humphreys, and P. Friedmann. 2015. Despite resources from the ACA, most states do little to help addiction treatment programs implement health care reform. Health Affairs 34(5):828–835.

Andrews, C. M., C. M. Grogan, M. A. Westlake, A. J. Abraham, H. A. Pollack, T. A. D’Aunno, and P. D. Friedmann. 2018. Do benefits restrictions limit Medicaid acceptance in addiction treatment?: Results from a national study. Journal of Substance Abuse Treatment 87:50–55.

Andrews, C. M., A. J. Abraham, C. M. Grogan, M. A. Westlake, H. A. Pollack, and P. D. Friedmann. 2019. Impact of Medicaid restrictions on availability of buprenorphine in addiction treatment programs. American Journal of Public Health 109(3):434–436.

Andrilla, C. H. A., C. Coulthard, and E. H. Larson. 2017a. Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Annals of Family Medicine 15(4):359–362.

Andrilla, C. H. A., C. Coulthard, and E. Larson. 2017b. Changes in the supply of physicians with a DEA DATA waiver to prescribe buprenorphine for opioid use disorder. Data Brief 162. WWAMI Rural Health Research Center, University of Washington, Seattle.

Andrilla, C. H. A., C. Coulthard, and D. G. Patterson. 2018a. Prescribing practices of rural physicians waivered to prescribe buprenorphine. American Journal of Preventive Medicine 54(6):S208–S214.

Andrilla, C. H. A., D. G. Patterson, T. E. Moore, C. Coulthard, and E. H. Larson. 2018b. Projected contributions of nurse practitioners and physician’s assistants to buprenorphine treatment services for opioid use disorder in rural areas. Medical Care Research and Review. doi: 10.1177/1077558718793070.

Andrilla, C. H. A., T. E. Moore, and D. G. Patterson. 2019a. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: Recommendations from rural physicians. Journal of Rural Health 35(1):113–121.

Andrilla, C. H. A., T. E. Moore, D. G. Patterson, and E. H. Larson. 2019b. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. Journal of Rural Health 35(1):108–112.

Antonini, V. P., B. T. Oeser, and D. Urada. 2012. The California integration learning collaborative: A forum to address challenges of SUD-primary care service integration. Journal of Psychoactive Drugs 44(4):285–291.

APA (American Psychological Association). 2017. Final rule: 42 CFR Part 2, confidentiality of substance use disorder patient records. https://www.psychiatry.org/psychiatrists/practice/practice-management/hipaa/42-cfr-part-2 (accessed October 15, 2019).

ASAM (American Society of Addiction Medicine). 2019. Harm reduction in the addiction continuum: Not as radical as one thinks (1.5 CME). https://elearning.asam.org/products/harm-reduction-in-the-addiction-continuum-not-as-radical-as-one-thinks-15-cme (accessed December 7, 2019).

Aspinall, E. J., D. Nambiar, D. J. Goldberg, M. Hickman, A. Weir, E. Van Velzen, N. Palmateer, J. S. Doyle, M. E. Hellard, and S. J. Hutchinson. 2014. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: A systematic review and meta-analysis. International Journal of Epidemiology 43(1):235–248.

Assoumou, S. A., A. Tasillo, C. Vellozzi, G. E. Yazdi, J. Wang, S. Nolen, L. Hagan, W. Thompson, L. M. Randall, L. Strick, J. A. Salomon, and B. P. Linas. 2019. Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons. Clinical Infectious Diseases. doi: 10.1093/cid/ciz383.

Avery, J., D. Knoepflmacher, E. Mauer, K. A. Kast, M. Greiner, J. Avery, and J. B. Penzner. 2019. Improvement in residents’ attitudes toward individuals with substance use disorders following an online training module on stigma. HSS Journal 15(1):31–36.

Azar, A., and B. Giroir. 2018. Strategy to combat opioid abuse, misuse, and overdose: A framework based on the five point strategy. https://www.hhs.gov/opioids/sites/default/files/2018-09/opioid-fivepoint-strategy-20180917-508compliant.pdf (accessed September 17, 2019).

Babor, T. F., B. G. McRee, P. A. Kassebaum, P. L. Grimaldi, K. Ahmed, and J. Bray. 2007. Screening, brief intervention, and referral to treatment (SBIRT): Toward a public health approach to the management of substance abuse. Substance Abuse 28(3):7–30.

Bachrach, D., S. Anthony, and A. Detty. 2014. State strategies for integrating physical and behavioral health services in a changing Medicaid environment. Los Angeles, CA: Manatt, Phelps & Phillips, LLP.

Bäck, D. K., E. Tammaro, J. K. Lim, and S. E. Wakeman. 2018. Massachusetts medical students feel unprepared to treat patients with substance use disorder. Journal of General Internal Medicine 33(3):249–250.

Bahora, M., S. Hanafi, V. H. Chien, and M. T. Compton. 2008. Preliminary evidence of effects of crisis intervention team training on self-efficacy and social distance. Administration and Policy in Mental Health and Mental Health Services Research 35(3):159–167.

Baillargeon, J., J. S. Pulvino, J. E. Leonardson, L. C. Linthicum, B. Williams, J. Penn, R. S. Williams, G. Baillargeon, and O. J. Murray. 2017. The changing epidemiology of HIV in the criminal justice system. International Journal of STD & AIDS 28(13):1335–1340.

Ball, A. L. 2007. HIV, injecting drug use and harm reduction: A public health response. Addiction 102(5):684–690.

Ballon, B. C., and W. Skinner. 2008. “Attitude is a little thing that makes a big difference”: Reflection techniques for addiction psychiatry training. Academic Psychiatry 32(3):218–224.

Batey, D. S., S. Whitfield, M. Mulla, K. L. Stringer, M. Durojaiye, L. McCormick, B. Turan, L. Nyblade, M.-C. Kempf, and J. M. Turan. 2016. Adaptation and implementation of an intervention to reduce HIV-related stigma among healthcare workers in the United States: Piloting of the fresh workshop. AIDS Patient Care and STDs 30(11):519–527.

Bavinton, B. R., A. N. Pinto, N. Phanuphak, B. Grinsztejn, G. P. Prestage, I. B. Zablotska-Manos, F. Jin, C. K. Fairley, R. Moore, N. Roth, M. Bloch, C. Pell, A. M. McNulty, D. Baker, J. Hoy, B. K. Tee, D. J. Templeton, D. A. Cooper, S. Emery, A. Kelleher, A. E. Grulich, I. B. Zablotska-Manos, G. P. Prestage, F. Jin, B. R. Bavinton, B. Grinsztejn, N. Phanuphak, D. A. Cooper, A. Kelleher, S. Emery, C. K. Fairley, D. Wilson, K. K. Koelsch, K. Triffitt, N. Doong, D. Baker, M. Bloch, D. J. Templeton, A. McNulty, C. Pell, J. Hoy, B. K. Tee, R. Moore, N. Roth, D. Orth, and A. N. Pinto. 2018. Viral suppression and HIV transmission in serodiscordant male couples: An international, prospective, observational, cohort study. The Lancet HIV 5(8):e438–e447.

Beetham, T. 2019. Buprenorphine prior authorization removal: Low hanging fruit in the opioid epidemic fight. Harvard Public Health Review 25. http://harvardpublichealthreview.org/buprenorphine (accessed December 10, 2019).

Belani, H. K., and P. A. Muennig. 2008. Cost-effectiveness of needle and syringe exchange for the prevention of HIV in New York City. Journal of HIV/AIDS & Social Services 7(3):229–240.

Beletsky, L., L. LaSalle, M. Newman, J. Paré, J. Tam, and A. Tochka. 2015. Fatal re-entry: Legal and programmatic opportunities to curb opioid overdose among individuals newly released from incarceration. Northeastern University Law Journal 7:149.

Bellis, M. A., K. Hughes, and H. Lowey. 2002. Healthy nightclubs and recreational substance use. From a harm minimisation to a healthy settings approach. Addictive Behaviors 27(6):1025–1035.

Berger, S. 2019. The opioid crisis: What we should learn from the AIDS epidemic. https://www.mailman.columbia.edu/public-health-now/news/opioid-crisis-what-we-should-learn-aids-epidemic (accessed October 16, 2019).

Bil, J. S. 2016. Stigma and architecture of mental health facilities. British Journal of Psychiatry 208(5):499–500.

Binswanger, I. A., P. J. Blatchford, S. R. Mueller, and M. F. Stern. 2013. Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Annals of Internal Medicine 159(9):592–600.

Bland, E., L. W. Oppenheimer, G. Brisson-Carroll, C. Morel, P. Holmes, and A. Gruslin. 2001. Influence of an educational program on medical students’ attitudes to substance use disorders in pregnancy. American Journal of Drug and Alcohol Abuse 27(3):483–490.

Botticelli, M. 2017. Changing federal terminology regarding substance use and substance use disorders. https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Memo%20-%20Changing%20Federal%20Terminology%20Regrading%20Substance%20Use%20and%20Substance%20Use%20Disorders.pdf (accessed August 26, 2019).

Bramson, H., D. C. Des Jarlais, K. Arasteh, A. Nugent, V. Guardino, J. Feelemyer, and D. Hodel. 2015. State laws, syringe exchange, and HIV among persons who inject drugs in the United States: History and effectiveness. Journal of Public Health Policy 36(2):212–230.

Brooklyn, J. R., and S. C. Sigmon. 2017. Vermont hub-and-spoke model of care for opioid use disorder: Development, implementation, and impact. Journal of Addiction Medicine 11(4):286.

Brookmeyer, K. A., L. T. Haderxhanaj, M. Hogben, and J. Leichliter. 2019. Sexual risk behaviors and STDs among persons who inject drugs: A national study. Preventive Medicine 126:105779.

Brown, D., and T. McGinnis. 2014. Considerations for integrating behavioral health services within Medicaid accountable care organizations. Hamilton, NJ: Center for Health Care Strategies, Inc.

Browne, T., M. A. Priester, S. Clone, A. Iachini, D. DeHart, and R. Hock. 2016. Barriers and facilitators to substance use treatment in the rural South: A qualitative study. Journal of Rural Health 32(1):92–101.

Buck, J. A. 2011. The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Affairs 30(8):1402–1410.

Budnitz, D. S. 2016. Notes from the field: Pediatric emergency department visits for buprenorphine/naloxone ingestion—United States, 2008–2015. Morbidity and Mortality Weekly Report 65.

Burns, R. M., R. L. Pacula, S. Bauhoff, A. J. Gordon, H. Hendrikson, D. L. Leslie, and B. D. Stein. 2016. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013. Substance Abuse 37(1):63–69.

Califano, J. A. 2010. Behind bars II: Substance abuse and America’s prison population. New York: National Center on Addiction and Substance Abuse at Columbia University.

Canadian HIV/AIDS Legal Network. 2006. Mandatory minimum sentences for drug offenses: Why everyone loses. Toronto, Ontario. http://www.aidslaw.ca/site/wp-content/uploads/2013/04/MMS_E.pdf (accessed December 4, 2019).

Canzater, S., and J. S. Crowley. 2019. Eliminating hepatitis C among people living with HIV in the United States: Leveraging the Ryan White HIV/AIDS Program to move us forward. Washington, DC: O’Neill Institute for National & Global Health Law.

Carroll, J. J., T. C. Green, and R. K. Noonan. 2018a. Evidence-based strategies for preventing opioid overdose: What’s working in the United States: An introduction for public health, law enforcement, local organizations, and others striving to serve their community. Centers for Disease Control and Prevention National Center for Injury Prevention and Control. https://www.cdc.gov/drugoverdose/pdf/pubs/2018-evidence-based-strategies.pdf (accessed November 26, 2019).

Carroll, J. J., J. D. Rich, and T. C. Green. 2018b. The more things change: Buprenorphine/naloxone diversion continues while treatment remains inaccessible. Journal of Addiction Medicine 12(6):459–465.

CDC (Centers for Disease Control and Prevention). 2003. Exposure to blood: What healthcare personnel need to know. Centers for Disease Control and Prevention. https://www.cdc.gov/hai/pdfs/bbp/exp_to_blood.pdf (accessed December 9, 2019).

CDC. 2014. Integrating infectious disease screening and prevention at substance abuse treatment centers. Centers for Disease Control and Prevention. https://www.cdc.gov/nchhstp/programintegration/successstories-tx/inf-disease-screening.html (accessed October 29, 2019).

CDC. 2015a. Diagnoses of HIV infection in the United States and dependent areas, 2014. Centers for Disease Control and Prevention. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2014-vol-26.pdf (accessed October 25, 2019).

CDC. 2015b. Factors increasing the risk of acquiring or transmitting HIV. Centers for Disease Control and Prevention. https://www.cdc.gov/hiv/pdf/risk/estimates/cdc-hiv-riskfactors.pdf (accessed November 27, 2019).

CDC. 2017. U.S. state prescribing rates, 2017. Centers for Disease Control and Prevention. https://www.cdc.gov/drugoverdose/maps/rxstate2017.html (accessed September 27, 2019).

CDC. 2018a. New data show growing complexity of drug overdose deaths in America. Centers for Disease Control and Prevention. https://www.cdc.gov/media/releases/2018/p1221complexity-drug-overdose.html (accessed September 27, 2019).

CDC. 2018b. Vulnerable counties and jurisdictions experiencing or at-risk of outbreaks. Centers for Disease Control and Prevention. https://www.cdc.gov/pwid/vulnerable-countiesdata.html (accessed September 18, 2019).

CDC. 2019a. Determination of need for syringe services programs. Centers for Disease Control and Prevention. https://www.cdc.gov/ssp/determination-of-need-for-ssp.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fhiv%2Frisk%2Fssps.html (accessed September 10, 2019).

CDC. 2019b. Diagnoses of HIV infection in the United States and dependent areas, 2018 (preliminary). Centers for Disease Control and Prevention. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2018-vol-30.pdf (accessed December 9, 2019).

CDC. 2019c. HIV and STD criminal laws. Centers for Disease Control and Prevention. https://www.cdc.gov/hiv/policies/law/states/exposure.html (accessed December 2, 2019).

CDC. 2019d. HIV in the United States by region. Centers for Disease Control and Prevention. https://www.cdc.gov/hiv/statistics/overview/geographicdistribution.html (accessed December 2, 2019).

CDC. 2019e. HIV risk behaviors. Centers for Disease Control and Prevention. https://www.cdc.gov/hiv/risk/estimates/riskbehaviors.html (accessed December 9, 2019).

CDC. 2019f. Promising state strategies. Centers for Disease Control and Prevention. https://www.cdc.gov/drugoverdose/policy/index.html (accessed September 17, 2019).

CDC. 2019g. STD prevention courses. Centers for Disease Control and Prevention. https://www.cdc.gov/std/training/courses.htm (accessed November 25, 2019).

Chandler, R. K., B. W. Fletcher, and N. D. Volkow. 2009. Treating drug abuse and addiction in the criminal justice system: Improving public health and safety. Journal of the American Medical Association 301(2):183–190.

Cheever, L. 2016. The evolution of Ryan White HIV/Care. HIV/AIDS Bureau, Health Resources and Services Administration, Department of Health and Human Services. https://www.hiv.gov/blog/the-evolution-of-ryan-white-hivcare (accessed December 2, 2019).

Chidrawi, H. C., M. Greeff, Q. M. Temane, and C. M. Doak. 2016. HIV stigma experiences and stigmatisation before and after an intervention. Health SA Gesondheid (Online) 21(1):195–205.

Christie, C. 2017. The President’s Commision on Combating Drug Addiction and the Opioid Crisis. https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Final_Report_Draft_11-1-2017.pdf (accessed August 23, 2019).

Cicero, T. J., M. S. Ellis, and H. D. Chilcoat. 2018. Understanding the use of diverted buprenorphine. Drug and Alcohol Dependence 193:117–123.

Cifuentes, M., M. Davis, D. Fernald, R. Gunn, P. Dickinson, and D. J. Cohen. 2015. Electronic health record challenges, workarounds, and solutions observed in practices integrating behavioral health and primary care. Journal of the American Board of Family Medicine 28(Supplement 1):S63–S72.

Clark, R. E., and J. D. Baxter. 2013. Responses of state Medicaid programs to buprenorphine diversion. JAMA Internal Medicine 173(17):1571.

Clark, R. E., M. Samnaliev, J. D. Baxter, and G. Y. Leung. 2011. The evidence doesn’t justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Affairs 30(8):1425–1433.

Clark, R. E., J. D. Baxter, B. A. Barton, G. Aweh, E. O’Connell, and W. H. Fisher. 2014. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Services Research 49(6):1964–1979.

Clemans-Cope, L., V. Lynch, E. Winiski, and M. Epstein. 2019. State variation in Medicaid prescriptions for opioid use disorder from 2011 to 2018. Policy Brief. Urban Institute.

Clifasefi, S. L., H. S. Lonczak, and S. E. Collins. 2017. Seattle’s Law Enforcement Assisted Diversion (LEAD) program: Within-subjects changes on housing, employment, and income/benefits outcomes and associations with recidivism. Crime & Delinquency 63(4):429–445.

CMS (Centers for Medicare & Medicaid Services). 2018. Announcement of calendar year (CY) 2019 Medicare Advantage capitation rates and Medicare Advantage and Part D payment policies and final call letter. Centers for Medicare & Medicaid Services. https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Announcement2019.pdf (accessed October 15, 2019).

CMS. 2019a. Federal policy guidance. Centers for Medicare & Medicaid Services. https://www.medicaid.gov/federal-policy-Guidance/index.html (accessed October 8, 2019).

CMS. 2019b. Medicaid state plan amendments. Centers for Medicare & Medicaid Services. https://www.medicaid.gov/state-resource-center/medicaid-state-plan-amendments/index.html (accessed December 9, 2019).

CMS. 2019c. Substance use disorders. Centers for Medicare & Medicaid Services. https://www.medicaid.gov/medicaid/benefits/bhs/substance-use-disorders/index.html (accessed August 19, 2019).

Cohen, M. S. 2019. Successful treatment of HIV eliminates sexual transmission. The Lancet 393(10189):2366–2367.

Cohen, M. S., Y. Q. Chen, M. McCauley, T. Gamble, M. C. Hosseinipour, N. Kumarasamy, J. G. Hakim, J. Kumwenda, B. Grinsztejn, J. H. Pilotto, S. V. Godbole, S. Chariyalertsak, B. R. Santos, K. H. Mayer, I. F. Hoffman, S. H. Eshleman, E. Piwowar-Manning, L. Cottle, X. C. Zhang, J. Makhema, L. A. Mills, R. Panchia, S. Faesen, J. Eron, J. Gallant, D. Havlir, S. Swindells, V. Elharrar, D. Burns, T. E. Taha, K. Nielsen-Saines, D. D. Celentano, M. Essex, S. E. Hudelson, A. D. Redd, T. R. Fleming, and H. S. Team. 2016. Antiretroviral therapy for the prevention of HIV-1 transmission. New England Journal of Medicine 375(9):830–839.

Cole, E. S., E. DiDomenico, G. Cochran, A. J. Gordon, W. F. Gellad, J. Pringle, J. Warwick, C.-C. H. Chang, J. Y. Kim, and J. Kmiec. 2019. The role of primary care in improving access to medication-assisted treatment for rural Medicaid enrollees with opioid use disorder. Journal of General Internal Medicine 34(6):936–943.

Connolly, B. 2019. How states address opioid use disorder in prisons. Philadelphia, PA: Pew Charitable Trusts.

Conrad, C., H. M. Bradley, D. Broz, S. Buddha, E. L. Chapman, R. R. Galang, D. Hillman, J. Hon, K. W. Hoover, M. R. Patel, A. Perez, P. J. Peters, P. Pontones, J. C. Roseberry, M. Sandoval, J. Shields, J. Walthall, D. Waterhouse, P. J. Weidle, H. Wu, J. M. Duwve, and CDC. 2015. Community outbreak of HIV infection linked to injection drug use of oxymorphone—Indiana, 2015. Morbidity and Mortality Weekly Report 64(16):443–444.

Conry-Cantilena, C., M. VanRaden, J. Gibble, J. Melpolder, A. O. Shakil, L. Viladomiu, L. Cheung, A. DiBisceglie, J. Hoofnagle, and J. W. Shih. 1996. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. New England Journal of Medicine 334(26):1691–1696.

Cook, J. E., V. Purdie-Vaughns, I. H. Meyer, and J. T. Busch. 2014. Intervening within and across levels: A multilevel approach to stigma and public health. Social Science & Medicine 103:101–109.

Cooper, H., L. Moore, S. Gruskin, and N. Krieger. 2005. The impact of a police drug crackdown on drug injectors’ ability to practice harm reduction: A qualitative study. Social Science & Medicine 61(3):673–684.

Cranston, K., C. Alpren, B. John, E. Dawson, K. Roosevelt, A. Burrage, J. Bryant, W. M. Switzer, C. Breen, P. J. Peters, T. Stiles, A. Murray, H. D. Fukuda, W. Adih, L. Goldman, N. Panneer, B. Callis, E. M. Campbell, L. Randall, A. M. France, R. M. Klevens, S. Lyss, S. Onofrey, C. Agnew-Brune, M. Goulart, H. Jia, M. Tumpney, P. McClung, S. Dasgupta, D. Bixler, K. Hampton, B. Amy, J. L. Jaeger, K. Buchacz, and A. DeMaria, Jr. 2019. Notes from the field: HIV diagnoses among persons who inject drugs—northeastern Massachusetts, 2015–2018. Morbidity and Mortality Weekly Report 68(10):253–254.

Cunningham, C. O., H. V. Kunins, R. J. Roose, R. T. Elam, and N. L. Sohler. 2007. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. Journal of General Internal Medicine 22(9):1325–1329.

Cunningham, C. O., A. Giovanniello, X. Li, H. V. Kunins, R. J. Roose, and N. L. Sohler. 2011. A comparison of buprenorphine induction strategies: Patient-centered home-based inductions versus standard-of-care office-based inductions. Journal of Substance Abuse Treatment 40(4):349–356.

D’Aunno, T., H. A. Pollack, L. Jiang, L. R. Metsch, and P. D. Friedmann. 2014. HIV testing in the nation’s opioid treatment programs, 2005–2011: The role of state regulations. Health Services Research 49(1):230–248.

Davis, C. S., and D. Carr. 2016. Physician continuing education to reduce opioid misuse, abuse, and overdose: Many opportunities, few requirements. Drug and Alcohol Dependence 163:100–107.

Davis, C. S., and D. H. Carr. 2019. Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States. International Journal of Drug Policy 73:42–48.

Davis, C. S., S. Ruiz, P. Glynn, G. Picariello, and A. Y. Walley. 2014. Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. American Journal of Public Health 104(8):e7–e9.

DEA (Drug Enforcement Administration). 2006. Dispensing controlled substances for the treatment of pain. https://www.deadiversion.usdoj.gov/fed_regs/notices/2006/fr09062.htm (accessed December 9, 2019).

DEA. 2019. Registration categories and fees. Drug Enforcement Administration Diversion Control Division. https://www.deadiversion.usdoj.gov/drugreg/categories.htm (accessed October 8, 2019).

Dean, L. T., M. C. Montgomery, J. Raifman, A. Nunn, T. Bertrand, A. Almonte, and P. A. Chan. 2018. The affordability of providing sexually transmitted disease services at a safety-net clinic. American Journal of Preventive Medicine 54(4):552–558.

Des Jarlais, D. C., S. R. Friedman, D. M. Novick, J. L. Sotheran, P. Thomas, S. R. Yancovitz, D. Mildvan, J. Weber, M. J. Kreek, and R. Maslansky. 1989. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. Journal of the American Medical Association 261(7):1008–1012.

Des Jarlais, D. C., C. McKnight, and J. Milliken. 2004. Public funding of US syringe exchange programs. Journal of Urban Health 81(1):118–121.

Des Jarlais, D. C., T. Perlis, K. Arasteh, L. V. Torian, S. Beatrice, J. Milliken, D. Mildvan, S. Yancovitz, and S. R. Friedman. 2005. HIV incidence among injection drug users in New York City, 1990 to 2002: Use of serologic test algorithm to assess expansion of HIV prevention services. American Journal of Public Health 95(8):1439–1444.

Des Jarlais, D. C., C. McKnight, C. Goldblatt, and D. Purchase. 2009. Doing harm reduction better: Syringe exchange in the United States. Addiction 104(9):1441–1446.

Des Jarlais, D. C., A. Nugent, A. Solberg, J. Feelemyer, J. Mermin, and D. Holtzman. 2015. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas—United States, 2013. Morbidity and Mortality Weekly Report 64(48):1337–1341.

DHCF (Department of Health Care Finance). 2016. Removal of prior authorization requirements for medication-assisted treatment. Government of the District of Columbia. https://dhcf.dc.gov/sites/default/files/dc/sites/dhcf/publication/attachments/DG852345_KT0000016252_1.pdf (accessed October 14, 2019).

Dick, A. W., R. L. Pacula, A. J. Gordon, M. Sorbero, R. M. Burns, D. Leslie, and B. D. Stein. 2015. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002–11. Health Affairs 34(6):1028–1034.

Dombrowski, J. C., M. Ramchandani, S. Dhanireddy, R. D. Harrington, A. Moore, and M. R. Golden. 2018. The Max Clinic: Medical care designed to engage the hardest-to-reach persons living with HIV in Seattle and King County, Washington. AIDS Patient Care and STDs 32(4):149–156.

Dowell, D., T. M. Haegerich, and R. Chou. 2016. CDC guideline for prescribing opioids for chronic pain—United States, 2016. Journal of the American Medical Association 315(15):1624–1645.

Ducharme, L. J., and A. J. Abraham. 2008. State policy influence on the early diffusion of buprenorphine in community treatment programs. Substance Abuse Treatment, Prevention, and Policy 3(1):17.

Dunn, K. E., D. A. Tompkins, G. E. Bigelow, and E. C. Strain. 2017. Efficacy of tramadol extended-release for opioid withdrawal: A randomized clinical trial. JAMA Psychiatry 74(9):885–893.

Dutta, A., A. L. Wirtz, S. Baral, C. Beyrer, and F. R. Cleghorn. 2012. Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. Current Opinion in HIV and AIDS 7(4):362–368.

Dwarakanath, M. 2019. The case for mandating buprenorphine training for pediatric resident physicians. JAMA Pediatrics 173(11):1013–1014.

Eckhardt, B. J., M. Scherer, E. Winkelstein, K. Marks, and B. R. Edlin. 2018. Hepatitis C treatment outcomes for people who inject drugs treated in an accessible care program located at a syringe service program. Open Forum Infectious Diseases 5(4):ofy048.

Ellis, M. S., Z. A. Kasper, and T. J. Cicero. 2018. Twin epidemics: The surging rise of methamphetamine use in chronic opioid users. Drug and Alcohol Dependence 193:14–20.

Englander, H., J. Gregg, J. Gullickson, O. Cochran-Dumas, C. Colasurdo, J. Alla, D. Collins, and C. Nicolaidis. 2019. Recommendations for integrating peer mentors in hospital-based addiction care. Substance Abuse 1–6: doi: 10.1080/08897077.

Fauci, A. S., and H. D. Marston. 2015. Ending the HIV–AIDS pandemic—follow the science. New England Journal of Medicine 373(23):2197–2199.

Feyissa, G. T., C. Lockwood, M. Woldie, and Z. Munn. 2019. Reducing HIV-related stigma and discrimination in healthcare settings: A systematic review of quantitative evidence. PLoS One 14(1):e0211298.

Fiellin, D. A., P. G. O’Connor, M. Chawarski, J. P. Pakes, M. V. Pantalon, and R. S. Schottenfeld. 2001. Methadone maintenance in primary care: A randomized controlled trial. Journal of the American Medical Association 286(14):1724–1731.

Finkelstein, R., J. Netherland, L. Sylla, M. N. Gourevitch, A. Cajina, L. Cheever, and B. Collaborative. 2011. Policy implications of integrating buprenorphine/naloxone treatment and HIV care. Journal of Acquired Immune Deficiency Syndromes 56:S98–S104.

Fiscella, K., S. E. Wakeman, and L. Beletsky. 2019. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder. JAMA Psychiatry 76(3):229.

Fleischauer, A. T., L. Ruhl, S. Rhea, and E. Barnes. 2017. Hospitalizations for endocarditis and associated health care costs among persons with diagnosed drug dependence—North Carolina, 2010–2015. Morbidity and Mortality Weekly Report 66(22):569–573.

Fox, A. D., M. R. Anderson, G. Bartlett, J. Valverde, J. L. Starrels, and C. O. Cunningham. 2014. Health outcomes and retention in care following release from prison for patients of an urban post-incarceration transitions clinic. Journal of Health Care for the Poor and Underserved 25(3):1139.

Frank, J. W., S. E. Wakeman, and A. J. Gordon. 2018. No end to the crisis without an end to the waiver. Substance Abuse 39(3):263–265.

Freudenberg, N., J. Daniels, M. Crum, T. Perkins, and B. E. Richie. 2005. Coming home from jail: The social and health consequences of community reentry for women, male adolescents, and their families and communities. American Journal of Public Health 95(10):1725–1736.

Frimpong, J. A. 2013. Missed opportunities for hepatitis C testing in opioid treatment programs. American Journal of Public Health 103(6):1028–1030.

FSMB (Federation of State Medical Boards). 2013. Model policy on DATA 2000 and treatment of opioid addiction in the medical office. Federation of State Medical Boards. http://www.fsmb.org/siteassets/advocacy/policies/model-policy-on-data-2000-and-treatment-of-opioid-addiction-in-the-medical-office.pdf (accessed December 1, 2019).

Gaither, J. R., V. Shabanova, and J. M. Leventhal. 2018. U.S. national trends in pediatric deaths from prescription and illicit opioids, 1999–2016. JAMA Network Open 1(8):e186558.

GAO (U.S. Government Accountability Office). 2018. Health care funding: Federal obligations to and expenditures by selected organizations involved in health-related activities, fiscal years 2013–2015. https://www.gao.gov/assets/700/690490.pdf (accessed December 9, 2019).

Gardner, E. M., M. P. McLees, J. F. Steiner, C. del Rio, and W. J. Burman. 2011. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clinical Infectious Diseases 52(6):793–800.

Gerberding, J. L. 1994. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: Final report from a longitudinal study. Journal of Infectious Diseases 170(6):1410–1417.

Ghitza, U., S. Sparenborg, and B. Tai. 2011. Improving drug abuse treatment delivery through adoption of harmonized electronic health record systems. Substance Abuse and Rehabilitation 2:125–131.

Golden, M. R., R. Lechtenberg, S. N. Glick, J. Dombrowski, J. Duchin, J. R. Reuer, S. Dhanireddy, S. Neme, and S. E. Buskin. 2019. Outbreak of human immunodeficiency virus infection among heterosexual persons who are living homeless and inject drugs—Seattle, Washington, 2018. Morbidity and Mortality Weekly Report 68(15):344–349.

Goldsmith, R. J. 2016. ASAM public policy statement on the definition of addiction, October 31, 2016. Chevy Chase, MD: American Society of Addiction Medicine.

Gonsalves, G. S., and F. W. Crawford. 2018. Dynamics of the HIV outbreak and response in Scott County, USA, 2011–15: A modelling study. The Lancet HIV 5(10):e569–e577.

Gordon, A. J., J. Liberto, S. Granda, S. Salmon-Cox, T. Andrée, and L. McNicholas. 2008. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. American Journal on Addictions 17(6):459–462.

Green, T. C., J. Clarke, L. Brinkley-Rubinstein, B. D. Marshall, N. Alexander-Scott, R. Boss, and J. D. Rich. 2018. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry 75(4):405–407.

Greenhalgh, T., G. Robert, F. Macfarlane, P. Bate, and O. Kyriakidou. 2004. Diffusion of innovations in service organizations: Systematic review and recommendations. Milbank Quarterly 82(4):581–629.

Gueronniere, G. D. L. 2019. State strategies to expand access to medication-assisted treatment (MAT) for opioid use disorder. Washington, DC: Legal Action Center.

Haffajee, R. L., and R. G. Frank. 2018. Making the opioid public health emergency effective. JAMA Psychiatry 75(8):767–768.

Haffajee, R. L., A. S. Bohnert, and P. A. Lagisetty. 2018. Policy pathways to address provider workforce barriers to buprenorphine treatment. American Journal of Preventive Medicine 54(6):S230–S242.

Hagan, H., D. Des Jarlais, S. R. Friedman, D. Purchase, and M. J. Alter. 1995. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. American Journal of Public Health 85(11):1531–1537.

Hagan, H., J. P. McGough, H. Thiede, S. Hopkins, J. Duchin, and E. R. Alexander. 2000. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. Journal of Substance Abuse Treatment 19(3):247–252.

Hagan, H., E. R. Pouget, and D. C. Des Jarlais. 2011. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. Journal of Infectious Diseases 204(1):74–83.

Hartard, C., C. Gantzer, J. P. Bronowicki, and E. Schvoerer. 2019. Emerging hepatitis E virus compared with hepatitis A virus: A new sanitary challenge. Reviews in Medical Virology 29(6):e2078.

Hartung, D. M., K. Johnston, J. Geddes, G. Leichtling, K. C. Priest, and P. T. Korthuis. 2019. Buprenorphine coverage in the Medicare Part D program for 2007 to 2018. Journal of the American Medical Association 321(6):607–609.

Hawk, K. F., F. E. Vaca, and G. D’Onofrio. 2015. Reducing fatal opioid overdose: Prevention, treatment and harm reduction strategies. Yale Journal of Biology and Medicine 88(3):235–245.

Hawk, M., R. W. S. Coulter, J. E. Egan, S. Fisk, M. Reuel Friedman, M. Tula, and S. Kinsky. 2017. Harm reduction principles for healthcare settings. Harm Reduction Journal 14(1):70.

Hawks, L., B. L. Norton, C. O. Cunningham, and A. D. Fox. 2016. The hepatitis C virus treatment cascade at an urban postincarceration transitions clinic. Journal of Viral Hepatitis 23(6):473–478.

He, T., K. Li, M. S. Roberts, A. C. Spaulding, T. Ayer, J. J. Grefenstette, and J. Chhatwal. 2016. Prevention of hepatitis C by screening and treatment in U.S. prisons. Annals of Internal Medicine 164(2):84–92.

Heath, B., P. Wise Romero, and K. Reynolds. 2013. A standard framework for levels of integrated healthcare. Washington, DC: SAMHSA-HRSA Center for Integrated Health Solutions.

Hedegaard, H., A. M. Miniño, and M. Warner. 2019. Urban–rural differences in drug overdose death rates, by sex, age, and type of drugs involved, 2017. Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/products/databriefs/db345.htm (accessed December 10, 2019).

Heijnders, M., and S. Van Der Meij. 2006. The fight against stigma: An overview of stigma-reduction strategies and interventions. Psychology, Health & Medicine 11(3):353–363.

Henderson, J. 2019. Community healthcare network calls on state to allow same-day billing. Crain’s New York Business, June 28.

HHS (Department of Health and Human Services). 2016. What is the HIV care continuum? https://www.hiv.gov/federal-response/policies-issues/hiv-aids-care-continuum (accessed September 18, 2019).

HHS. 2019a. A timeline of HIV and AIDS. https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline (accessed October 16, 2019).

HHS. 2019b. HHS 42 CFR Part 2 proposed rule fact sheet. https://www.hhs.gov/about/news/2019/08/22/hhs-42-cfr-part-2-proposed-rule-fact-sheet.html (accessed October 3, 2019).

HHS. 2019c. What is “Ending the HIV Epidemic: A Plan for America”? https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview (accessed December 9, 2019).

HHS. 2019d. What is the U.S. opioid epidemic? https://www.hhs.gov/opioids/about-theepidemic/index.html (accessed October 16, 2019).

Houy, M., and M. Bailit. 2015. Barriers to behavioral and physical health integration in Massachusetts. Blue Cross Blue Shield Foundation of Massachusetts.

HPP (Health Policy Project). 2011. Comprehensive package for reducing stigma and discrimination in health facilities. U.S. Agency for International Development.

HRC (Harm Reduction Coalition). 2019. Principles of harm reduction. https://harmreduction.org/about-us/principles-of-harm-reduction (accessed December 9, 2019).

HRI (Harm Reduction International). 2019. What is harm reduction? https://www.hri.global/what-is-harm-reduction (accessed September 16, 2019).

HRSA (Health Resources and Services Administration). 2018. Ryan White HIV/AIDS program annual client-level data report 2017. Health Resources and Services Administration https://hab.hrsa.gov/sites/default/files/hab/data/datareports/RWHAP-annualclient-level-data-report-2017.pdf (accessed September 17, 2019).

HRSA. 2019a. About the Ryan White HIV/AIDS program. https://hab.hrsa.gov/about-ryan-whitehivaids-program/about-ryan-white-hivaids-program (accessed September 17, 2019).

HRSA. 2019b. Behavioral health. https://bhw.hrsa.gov/grants/behavioral-health (accessed October 22, 2019).

HRSA. 2019c. NHSC Rural Community Loan Repayment Program. https://nhsc.hrsa.gov/loanrepayment/nhsc-rural-community-loan-repayment-program (accessed August 26, 2019).

HRSA. 2019d. Telehealth programs. https://www.hrsa.gov/rural-health/telehealth/index.html (accessed October 22, 2019).

Hser, Y. I., A. J. Saxon, D. Huang, A. Hasson, C. Thomas, M. Hillhouse, P. Jacobs, C. Teruya, P. McLaughlin, and K. Wiest. 2014. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 109(1):79–87.

Hu, L. L., S. Sparenborg, and B. Tai. 2011. Privacy protection for patients with substance use problems. Substance Abuse and Rehabilitation 2:227–233.

Huhn, A. S., and K. E. Dunn. 2017. Why aren’t physicians prescribing more buprenorphine? Journal of Substance Abuse Treatment 78:1–7.

Hutchinson, E., M. Catlin, C. H. A. Andrilla, L.-M. Baldwin, and R. A. Rosenblatt. 2014. Barriers to primary care physicians prescribing buprenorphine. Annals of Family Medicine 12(2):128–133.

IOM (Institute of Medicine). 1995. Federal regulation of methadone treatment. Washington, DC: National Academy Press.

Islam, M. M., L. Topp, K. M. Conigrave, A. White, S. E. Reid, S. Grummett, P. S. Haber, and C. A. Day. 2012. Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. Journal of Substance Abuse Treatment 43(4):440–445.

Jackson, K. A., M. K. Bohm, J. T. Brooks, A. Asher, J. Nadle, W. M. Bamberg, S. Petit, S. M. Ray, L. H. Harrison, R. Lynfield, G. Dumyati, W. Schaffner, J. M. Townes, and I. See. 2018. Invasive methicillin-resistant Staphylococcus aureus infections among persons who inject drugs—six sites, 2005–2016. Morbidity and Mortality Weekly Report 67(22):625–628.

Jensen, E. L., J. Gerber, and C. Mosher. 2004. Social consequences of the war on drugs: The legacy of failed policy. Criminal Justice Policy Review 15(1):100–121.

Jin, H., A. Ogunbajo, M. J. Mimiaga, D. T. Duncan, E. Boyer, P. Chai, S. E. Dilworth, and A. W. Carrico. 2018. Over the influence: The HIV care continuum among methamphetamine-using men who have sex with men. Drug and Alcohol Dependence 192:125–128.

Johnson, B., and T. Richert. 2015. Diversion of methadone and buprenorphine from opioid substitution treatment: The importance of patients’ attitudes and norms. Journal of Substance Abuse Treatment 54:50–55.

Jones, C. M. 2019. Syringe services programs: An examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the US. International Journal of Drug Policy 70:22–32.

Jones, C. M., and E. F. McCance-Katz. 2019. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction 114(3):471–482.

Joudrey, P. J., J. Edelman, and E. A. Wang. 2019. Drive times to opioid treatment programs in urban and rural counties in 5 US states. Journal of the American Medical Association 322(13):1310–1312.

Katz, I. T., A. E. Ryu, A. G. Onuegbu, C. Psaros, S. D. Weiser, D. R. Bangsberg, and A. C. Tsai. 2013. Impact of HIV-related stigma on treatment adherence: Systematic review and meta-synthesis. Journal of the International AIDS Society 16:18640.

Kay, E. S., D. S. Batey, and M. J. Mugavero. 2018. The Ryan White HIV/AIDS program: Supplementary service provision post-Affordable Care Act. AIDS Patient Care and STDs 32(7):265–271.

Kelly, J. F., and C. M. Westerhoff. 2010. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. International Journal of Drug Policy 21(3):202–207.

Kelly, J. F., R. Saitz, and S. Wakeman. 2016. Language, substance use disorders, and policy: The need to reach consensus on an “addiction-ary.” Alcoholism Treatment Quarterly 34(1):116–123.

Kennedy-Hendricks, A., S. H. Busch, E. E. McGinty, M. A. Bachhuber, J. Niederdeppe, S. E. Gollust, D. W. Webster, D. A. Fiellin, and C. L. Barry. 2016. Primary care physicians’ perspectives on the prescription opioid epidemic. Drug and Alcohol Dependence 165:61–70.

Kennedy-Hendricks, A., C. L. Barry, S. E. Gollust, M. E. Ensminger, M. S. Chisolm, and E. E. McGinty. 2017. Social stigma toward persons with prescription opioid use disorder: Associations with public support for punitive and public health–oriented policies. Psychiatric Services 68(5):462–469.

Kepple, N. J., A. Parker, S. Whitmore, and M. Comtois. 2019. Nowhere to go? Examining facility acceptance levels for serving individuals using medications for opioid use disorder. Journal of Substance Abuse Treatment 104:42–50.

Kidd, S. E., J. A. Grey, E. A. Torrone, and H. S. Weinstock. 2019. Increased methamphetamine, injection drug, and heroin use among women and heterosexual men with primary and secondary syphilis—United States, 2013–2017. Morbidity and Mortality Weekly Report 68(6):144–148.

Kim, H. K., M. Smiddy, R. S. Hoffman, and L. S. Nelson. 2012. Buprenorphine may not be as safe as you think: A pediatric fatality from unintentional exposure. Pediatrics 130(6):e1700–e1703.

Kinlock, T. W., M. S. Gordon, R. P. Schwartz, and K. E. O’Grady. 2008. A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. Criminal Justice and Behavior 35(1):34–47.

Knopf, A. 2019. ASAM supports eliminating the X-waiver for buprenorphine. Alcoholism & Drug Abuse Weekly 31(29):6–7.

Knudsen, H. K. 2015. The supply of physicians waivered to prescribe buprenorphine for opioid use disorders in the United States: A state-level analysis. Journal of Studies on Alcohol and Drugs 76(4):644–654.

Knudsen, H. K., M. R. Lofwall, J. R. Havens, and S. L. Walsh. 2015. States’ implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence. Drug and Alcohol Dependence 157:36–43.

Knudsen, H. K., L. Lin, and M. R. Lofwall. 2019. Adoption of the 275-patient buprenorphine treatment waiver for treating opioid use disorder: A state-level longitudinal analysis. Substance Abuse 1–10. doi: 10.1080/08897077.2019.1635959.

Kolodny, A., D. T. Courtwright, C. S. Hwang, P. Kreiner, J. L. Eadie, T. W. Clark, and G. C. Alexander. 2015. The prescription opioid and heroin crisis: A public health approach to an epidemic of addiction. Annual Review of Public Health 36:559–574.

Kultys, K. 2019. Gov. Phil Murphy announces new initiatives to combat opioid epidemic. Burlington County Times, January 23.

Lambrew, J. 2019. Transmittal and notice of approval of state plan material. https://www.medicaid.gov/State-resource-center/Medicaid-State-Plan-Amendments/Downloads/ME/ME-19-0012.pdf (accessed December 12, 2019).

Lavonas, E. J., S. G. Severtson, E. M. Martinez, B. Bucher-Bartelson, M.-C. Le Lait, J. L. Green, L. E. Murrelle, T. J. Cicero, S. P. Kurtz, and A. Rosenblum. 2014. Abuse and diversion of buprenorphine sublingual tablets and film. Journal of Substance Abuse Treatment 47(1):27–34.

Law, M. R., S. B. Soumerai, D. Ross-Degnan, and A. S. Adams. 2008. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. Journal of Clinical Psychiatry 69(1):47–53.

Lee, J. D., E. Grossman, D. DiRocco, and M. N. Gourevitch. 2009. Home buprenorphine/naloxone induction in primary care. Journal of General Internal Medicine 24(2):226–232.

Lee, J. D., F. Vocci, and D. A. Fiellin. 2014. Unobserved “home” induction onto buprenorphine. Journal of Addiction Medicine 8(5):299–308.

Lee, J. D., P. D. Friedmann, T. W. Kinlock, E. V. Nunes, T. Y. Boney, R. A. Hoskinson, Jr., D. Wilson, R. McDonald, J. Rotrosen, and M. N. Gourevitch. 2016. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. New England Journal of Medicine 374(13):1232–1242.

Lembke, A., and K. Humphreys. 2018. The opioid epidemic as a watershed moment for physician training in addiction medicine. Academic Psychiatry 42(2):269–272.

Lerner, A. M., and A. S. Fauci. 2019. Opioid injection in rural areas of the United States: A potential obstacle to ending the HIV epidemic. Journal of the American Medical Association 322(11):1041–1042.

Li, X., D. Shorter, and T. R. Kosten. 2016. Buprenorphine prescribing. Journal of Psychiatric Practice 22(3):183–192.

Lin, L. A., M. R. Lofwall, S. L. Walsh, A. J. Gordon, and H. K. Knudsen. 2018. Perceptions and practices addressing diversion among U.S. buprenorphine prescribers. Drug and Alcohol Dependence 186:147–153.

Link, B. G., and J. C. Phelan. 2001. Conceptualizing stigma. Annual Review of Sociology 27(1):363–385.

Link, B. G., E. L. Struening, M. Rahav, J. C. Phelan, and L. Nuttbrock. 1997. On stigma and its consequences: Evidence from a longitudinal study of men with dual diagnoses of mental illness and substance abuse. Journal of Health and Social Behavior 38:177–190.

Livingston, J. D., T. Milne, M. L. Fang, and E. Amari. 2012. The effectiveness of interventions for reducing stigma related to substance use disorders: A systematic review. Addiction 107(1):39–50.

Lofwall, M. R., and J. R. Havens. 2012. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug and Alcohol Dependence 126(3):379–383.

Lofwall, M. R., and S. L. Walsh. 2014. A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world. Journal of Addiction Medicine 8(5):315–326.

Lopez, K., and D. Reid. 2017. Discrimination against patients with substance use disorders remains prevalent and harmful: The case for 42 CFR Part 2. Health Affairs. https://www.healthaffairs.org/do/10.1377/hblog20170413.059618/full (accessed August 22, 2019).

Lu, C. Y., M. R. Law, S. B. Soumerai, A. J. Graves, R. F. Lecates, F. Zhang, D. Ross-Degnan, and A. S. Adams. 2011. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: Results of a longitudinal, population-based study. Clinical Therapeutics 33(1):135–144.

Lucas, G. M., P. J. Weidle, S. Hader, and R. D. Moore. 2004. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: A nonrandomized comparative study. Clinical Infectious Diseases 38(Supplement 5):S409–S413.

Lucas, G. M., A. Chaudhry, J. Hsu, T. Woodson, B. Lau, Y. Olsen, J. C. Keruly, D. A. Fiellin, R. Finkelstein, and P. Barditch-Crovo. 2010. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Annals of Internal Medicine 152(11):704–711.

Maclean, J. C., and B. Saloner. 2019. The effect of public insurance expansions on substance use disorder treatment: Evidence from the Affordable Care Act. Journal of Policy Analysis and Management 38(2):366–393.

MACPAC (Medicaid and CHIP Payment and Access Commission). 2018a. Medicaid and the criminal justice system. Medicaid and CHIP Payment and Access Commission. https://www.macpac.gov/publication/medicaid-and-the-criminal-justice-system (accessed September 16, 2019).

MACPAC. 2018b. Substance use disorder confidentiality regulations and care integration in Medicaid and CHIP. https://www.macpac.gov/wp-content/uploads/2018/06/Substance-Use-Disorder-Confidentiality-Regulations-and-Care-Integration-in-Medicaid-and-CHIP.pdf (accessed October 15, 2019).

Madras, B. K., W. M. Compton, D. Avula, T. Stegbauer, J. B. Stein, and H. W. Clark. 2009. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and 6 months later. Drug and Alcohol Dependence 99(1–3):280–295.

Malivert, M., M. Fatséas, C. Denis, E. Langlois, and M. Auriacombe. 2012. Effectiveness of therapeutic communities: A systematic review. European Addiction Research 18(1):1–11.

Mark, T., J. Richardson, and H. Lin. 2014. Medicaid coverage and financing of medications to treat alcohol and opioid use disorders. Rockville, MD: Truven Health Analytics Inc.

Mark, T. L., W. Parish, and G. A. Zarkin. 2019. Association between Medicare and FDA policies and prior authorization requirements for buprenorphine products in Medicare Part D plans. Journal of the American Medical Association 322(2):166–167.

Marks, L. R., S. Munigala, D. K. Warren, S. Y. Liang, E. S. Schwarz, and M. J. Durkin. 2018. Addiction medicine consultations reduce readmission rates for patients with serious infections from opioid use disorder. Clinical Infectious Diseases 68(11):1935–1937.

Marlatt, G. A. 1996. Harm reduction: Come as you are. Addictive Behaviors 21(6):779–788.

Marlatt, G. A., and K. Witkiewitz. 2010. Update on harm-reduction policy and intervention research. Annual Review of Clinical Psychology 6:591–606.

Martin, S. A., L. M. Chiodo, J. D. Bosse, and A. Wilson. 2018. The next stage of buprenorphine care for opioid use disorder. Annals of Internal Medicine 169(9):628–635.

Masyukova, M. I., D. B. Hanna, and A. D. Fox. 2018. HIV treatment outcomes among formerly incarcerated transitions clinic patients in a high prevalence setting. Health & Justice 6(1):16.

Mauer, B. J. 2010. Substance use disorders and the person-centered healthcare home. National Council for Behavioral Healthcare. https://www.integration.samhsa.gov/integratedcare-models/National_Council_SU_Report.pdf (accessed January 8, 2020).

McCance-Katz, E. F., P. M. Rainey, G. Friedland, and P. Jatlow. 2003. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clinical Infectious Diseases 37(4):476–482.

McCance-Katz, E. F., P. George, N. A. Scott, R. Dollase, A. R. Tunkel, and J. McDonald. 2017. Access to treatment for opioid use disorders: Medical student preparation. American Journal on Addictions 26(4):316–318.

McCarty, D., T. Rieckmann, R. L. Baker, and K. J. McConnell. 2016. The perceived impact of 42 CFR Part 2 on coordination and integration of care: A qualitative analysis. Psychiatric Services 68(3):245–249.

McKenzie, M., A. Nunn, N. D. Zaller, A. R. Bazazi, and J. D. Rich. 2009. Overcoming obstacles to implementing methadone maintenance therapy for prisoners: Implications for policy and practice. Journal of Opioid Management 5(4):219–227.

McLellan, A. T., and A. M. Woodworth. 2014. The Affordable Care Act and treatment for “substance use disorders”: Implications of ending segregated behavioral healthcare. Journal of Substance Abuse Treatment 46(5):541–545.

McLellan, A. T., D. C. Lewis, C. P. O’Brien, and H. D. Kleber. 2000. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. Journal of the American Medical Association 284(13):1689–1695.

McLuckie, C., M. T. Pho, K. Ellis, L. Navon, K. Walblay, W. D. Jenkins, C. Rodriguez, M. A. Kolak, Y. T. Chen, J. A. Schneider, and W. E. Zahnd. 2019. Identifying areas with disproportionate local health department services relative to opioid overdose, HIV and hepatitis C diagnosis rates: A study of rural Illinois. International Journal of Environmental Research and Public Health 16(6):989.

Meinhofer, A., A. R. Williams, P. Johnson, B. R. Schackman, and Y. Bao. 2019. Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events? Journal of Substance Abuse Treatment 105:37–43.

Meireles, L. C., R. T. Marinho, and P. Van Damme. 2015. Three decades of hepatitis B control with vaccination. World Journal of Hepatology 7(18):2127–2132.

Meng, C., B. B. Rayburn, W. A. Ramirez-Cacho, and W. F. Rayburn. 2007. Effect of a specialized prenatal clinic on medical student attitudes toward women with drinking problems. Journal of Maternal-Fetal & Neonatal Medicine 20(3):217–220.

Merrill, J. O. 2003. Integrating medical care and addiction treatment. Journal of General Internal Medicine 18(1):68–69.

Meyer, J. P., J. Cepeda, S. A. Springer, J. Wu, R. L. Trestman, and F. L. Altice. 2014. HIV in people reincarcerated in Connecticut prisons and jails: An observational cohort study. The Lancet HIV 1(2):e77–e84.

MHAF (Minority HIV/AIDS Fund). 2018. Substance use and HIV risk. https://www.hiv.gov/hiv-basics/hiv-prevention/reducing-risk-from-alcohol-and-drug-use/substance-use-and-HIV-risk (accessed November 26, 2019).

Miller, B. F., M. R. Talen, and K. K. Patel. 2013. Advancing integrated behavioral health and primary care: The critical importance of behavioral health in health care policy. Integrated Behavioral Health in Primary Care. New York: Springer Science+Business Media. Pp. 53–62.

Mitchell, O., and M. S. Caudy. 2017. Race differences in drug offending and drug distribution arrests. Crime & Delinquency 63(2):91–112.

Mojtabai, R., K. A. Feder, M. Kealhofer, N. Krawczyk, C. Storr, K. N. Tormohlen, A. S. Young, M. Olfson, and R. M. Crum. 2018. State variations in Medicaid enrollment and utilization of substance use services: Results from a national longitudinal study. Journal of Substance Abuse Treatment 89:75–86.

Monson, S. P., J. C. Sheldon, L. C. Ivey, C. R. Kinman, and A. O. Beacham. 2012. Working toward financial sustainability of integrated behavioral health services in a public health care system. Families, Systems, & Health 30(2):181.

Moore, L. D., and A. Elkavich. 2008. Who’s using and who’s doing time: Incarceration, the war on drugs, and public health. American Journal of Public Health 98(Supplement 1): S176–S180.

Morris, M. D., B. Brown, and S. A. Allen. 2017. Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health. International Journal of Prisoner Health 13(3/4):192–199.

Mosher, J. F., and K. L. Yanagisako. 1991. Public health, not social warfare: A public health approach to illegal drug policy. Journal of Public Health Policy 12(3):278–323.

NACRHHS (National Advisory Committee on Rural Health and Human Services). 2015. Mortality and life expectancy in rural America: Connecting the health and human service safety nets to improve health outcomes over the life course. Rockville, MD: National Advisory Committee on Rural Health and Human Services.

NASEM (National Academies of Sciences, Engineering, and Medicine). 2016a. Eliminating the public health problem of hepatitis B and C in the United States: Phase one report. Washington, DC: The National Academies Press.

NASEM. 2016b. Ending discrimination against people with mental and substance use disorders: The evidence for stigma change. Washington, DC: The National Academies Press.

NASEM. 2017. A national strategy for the elimination of hepatitis B and C: Phase two report. Washington, DC: The National Academies Press.

NASEM. 2019. Medications for opioid use disorder save lives. Washington, DC: The National Academies Press.

NCASA (National Center on Addiction and Substance Abuse). 2012. Addiction medicine: Closing the gap between science and practice. New York: The National Center on Addiction and Substance Abuse at Columbia University.

NCASA. 2017. Ending the opioid crisis: A practical guide for state policymakers. New York: The National Center on Addiction and Substance Abuse at Columbia University.

NCSL (National Conference of State Legislatures). 2017. Understanding Medicaid Section 1115 waivers: A primer for state legislators. Washington, DC.

Nerlander, L. M., K. L. Hess, C. Sionean, C. E. Rose, A. Thorson, D. Broz, and G. Paz-Bailey. 2017. Exchange sex and HIV infection among men who have sex with men: 20 U.S. cities, 2011. AIDS and Behavior 21(8):2283–2294.

Nguyen, T. Q., B. W. Weir, D. C. Des Jarlais, S. D. Pinkerton, and D. R. Holtgrave. 2014. Syringe exchange in the United States: A national level economic evaluation of hypothetical increases in investment. AIDS and Behavior 18(11):2144–2155.

Nicholas, J. 2019. Drug treatment is reaching more prisons and jails. https://theappeal.org/a-shot-over-the-bow-to-all-jails-and-prisons (accessed September 16, 2019).

NIDA (National Institute on Drug Abuse). 2011. Principles of drug addiction treatment: A research-based guide. 2nd ed. NIH Publication No. 094180.

NIDA. 2018a. Medications to treat opioid use disorder. National Institute on Drug Abuse. https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioidaddiction/overview (accessed September 17, 2019).

NIDA. 2018b. Viral hepatitis—a very real consequence of substance use. National Institute on Drug Abuse. https://www.drugabuse.gov/related-topics/viral-hepatitis-very-real-consequence-substance-use (accessed October 16, 2019).

NIDA. 2018c. What is the impact of medication for opioid use disorder treatment on HIV/HCV outcomes? National Institute on Drug Abuse. https://www.drugabuse.gov/publications/medications-to-treat-opioid-addiction/what-impact-medication-opioid-use-disordertreatment-hivhcv-outcomes (accessed December 3, 2019).

NIDA. 2018d. What is the treatment need versus the diversion risk for opioid use disorder treatment? National Institute on Drug Abuse. https://www.drugabuse.gov/publications/medications-to-treat-opioid-addiction/what-treatment-need-versus-diversion-riskopioid-use-disorder-treatment (accessed November 27, 2019).

NIDA. 2019. Overdose death rates. National Institute on Drug Abuse. https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates (accessed October 17, 2019).

Noonan, R. 2017. Rural America in crisis: The changing opioid overdose epidemic. https://blogs.cdc.gov/publichealthmatters/2017/11/opioids (accessed January 8, 2020).

NRC (National Research Council). 1995. Preventing HIV transmission: The role of sterile needles and bleach. Washington DC: National Academy Press.

NRC. 2014. The growth of incarceration in the United States: Exploring causes and consequences. Washington, DC: The National Academies Press.

Nyblade, L., K. Srinivasan, A. Mazur, T. Raj, D. S. Patil, D. Devadass, K. Radhakrishna, and M. L. Ekstrand. 2018. HIV stigma reduction for health facility staff: Development of a blended-learning intervention. Frontiers in Public Health 6:165.

Nyblade, L., M. A. Stockton, K. Giger, V. Bond, M. L. Ekstrand, R. Mc Lean, E. M. Mitchell, E. N. La Ron, J. C. Sapag, and T. Siraprapasiri. 2019. Stigma in health facilities: Why it matters and how we can change it. BMC Medicine 17(1):25.

O’Brien, J., T. Sadwith, C. Croze, and S. Parker. 2019. Review of state strategies to expand medication-assisted treatment. Boston, MA: Technical Assistance Collaborative.

O’Connor, P. G., R. J. Sokol, and G. D’Onofrio. 2014. Addiction medicine: The birth of a new discipline. JAMA Internal Medicine 174(11):1717–1718.

OCR (Office for Civil Rights). 2013. Summary of the HIPAA privacy rule. https://www.hhs.gov/hipaa/for-professionals/privacy/laws-regulations/index.html (accessed August 22, 2019).

Olsen, Y., and J. M. Sharfstein. 2014. Confronting the stigma of opioid use disorder—and its treatment. Journal of the American Medical Association 311(14):1393–1394.

Park, Y., S. Raza, A. George, R. Agrawal, and J. Ko. 2017. The effect of formulary restrictions on patient and payer outcomes: A systematic literature review. Journal of Managed Care & Specialty Pharmacy 23(8):893–901.

Parks, T. 2017. AGS called on to help stop prior authorization for MAT. https://www.ama-assn.org/practice-management/sustainability/ags-called-help-stop-prior-authorizationmat (accessed November 25, 2019).

Pating, D. R., M. M. Miller, E. Goplerud, J. Martin, and D. M. Ziedonis. 2012. New systems of care for substance use disorders: Treatment, finance, and technology under health care reform. Psychiatric Clinics 35(2):327–356.

PCORI (Patient-Centered Outcomes Research Institute). 2019. Comparing ways to provide hepatitis C treatment for people who take methadone. https://www.pcori.org/researchresults/2016/comparing-ways-provide-hepatitis-c-treatment-people-who-takemethadone (accessed October 8, 2019).

PCSS (Providers Clinical Support System). 2019a. 8 hour MAT waiver training. https://pcssnow.org/calendar-of-events/map/?tribe_eventcategory=181 (accessed October 8, 2019).

PCSS. 2019b. Mentors. https://pcssnow.org/mentoring/mentors (accessed December 5, 2019).

PCSS. 2019c. Training courses. https://pcssnow.org/education-training/training-courses/?topic=buprenorphine&cme=cme (accessed December 7, 2019).

Perlman, D. C., and A. E. Jordan. 2017. Considerations for the development of a substance-related care and prevention continuum model. Frontiers in Public Health 5:180.

Platt, L., J. E. Reed, H. Hagan, A. E. Jordan, P. Vickerman, and M. Hickman. 2016. Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. Addiction 113(3):545–563.

Priester, M. A., T. Browne, A. Iachini, S. Clone, D. DeHart, and K. D. Seay. 2016. Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: An integrative literature review. Journal of Substance Abuse Treatment 61:47–59.

Ram, A., and M. S. Chisolm. 2016. The time is now: Improving substance abuse training in medical schools. Academic Psychiatry 40(3):454–460.

Ranapurwala, S. I., M. E. Shanahan, A. A. Alexandridis, S. K. Proescholdbell, R. B. Naumann, D. Edwards, Jr., and S. W. Marshall. 2018. Opioid overdose mortality among former North Carolina inmates: 2000–2015. American Journal of Public Health 108(9):1207–1213.

Rao, D., A. Elshafei, M. Nguyen, M. L. Hatzenbuehler, S. Frey, and V. F. Go. 2019. A systematic review of multi-level stigma interventions: State of the science and future directions. BMC Medicine 17(1):41.

Rao, H., H. Mahadevappa, P. Pillay, M. Sessay, A. Abraham, and J. Luty. 2009. A study of stigmatized attitudes towards people with mental health problems among health professionals. Journal of Psychiatric and Mental Health Nursing 16(3):279–284.

Rasyidi, E., J. N. Wilkins, and I. Danovitch. 2012. Training the next generation of providers in addiction medicine. Psychiatric Clinics of North America 35(2):461–480.

Ratycz, M. C., T. J. Papadimos, and A. A. Vanderbilt. 2018. Addressing the growing opioid and heroin abuse epidemic: A call for medical school curricula. Medical Education Online 23(1):1466574.

Redford, A., and B. Powell. 2016. Dynamics of intervention in the war on drugs: The buildup to the Harrison Act of 1914. The Independent Review 20(4):509–530.

Rementer, E. 2018. Wolf administration announces agreement with insurers to eliminate barriers to medication-assisted treatment. Pennsylvania Pressroom. https://www.media.pa.gov/Pages/Insurance-Details.aspx?newsid=344 (accessed December 10, 2019).

Rich, J. D., M. McKenzie, G. E. Macalino, L. E. Taylor, S. Sanford-Colby, F. Wolf, S. McNamara, M. Mehrotra, and M. D. Stein. 2004. A syringe prescription program to prevent infectious disease and improve health of injection drug users. Journal of Urban Health 81(1):122–134.

Rich, J. D., S. A. Allen, and B. A. Williams. 2014. Responding to hepatitis C through the criminal justice system. New England Journal of Medicine 370(20):1871–1874.

Rinaldo, S. G., and D. W. Rinaldo. 2013. Availability without accessibility? State Medicaid coverage and authorization requirements for opioid dependence medications. Chevy Chase, MD: American Society of Addiction Medicine.

Ritter, A., and J. Cameron. 2006. A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs. Drug and Alcohol Review 25(6):611–624.

Roby, D. H., and E. E. Jones. 2016. Limits on same-day billing in Medicaid hinders integration of behavioral health into the medical home model. Psychological Services 13(1):110–119.

Roche, A. M., K. R. Evans, and W. R. Stanton. 1997. Harm reduction: Roads less travelled to the holy grail. Addiction 92(9):1207–1212.

Rodger, A. J., V. Cambiano, T. Bruun, P. Vernazza, S. Collins, J. van Lunzen, G. M. Corbelli, V. Estrada, A. M. Geretti, A. Beloukas, D. Asboe, P. Viciana, F. Gutierrez, B. Clotet, C. Pradier, J. Gerstoft, R. Weber, K. Westling, G. Wandeler, J. M. Prins, A. Rieger, M. Stoeckle, T. Kümmerle, T. Bini, A. Ammassari, R. Gilson, I. Krznaric, M. Ristola, R. Zangerle, P. Handberg, A. Antela, S. Allan, A. N. Phillips, J. Lundgren, and P. S. Group. 2016. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. Journal of the American Medical Association 316(2):171–181.

Rodger, A. J., V. Cambiano, T. Bruun, P. Vernazza, S. Collins, O. Degen, G. M. Corbelli, et al. 2019. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (partner): Final results of a multicentre, prospective, observational study. The Lancet 393(10189):2428–2438.

Ronan, M. V., and S. J. Herzig. 2016. Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002–12. Health Affairs 35(5):832–837.

Rosenthal, R. N., and V. V. Goradia. 2017. Advances in the delivery of buprenorphine for opioid dependence. Drug Design, Development and Therapy 11:2493.

Rudd, R. A., L. J. Paulozzi, M. J. Bauer, R. W. Burleson, R. E. Carlson, D. Dao, J. W. Davis, J. Dudek, B. A. Eichler, J. C. Fernandes, A. Fondario, B. Gabella, B. Hume, T. Huntamer, M. Kariisa, T. W. Largo, J. Miles, A. Newmyer, D. Nitcheva, B. E. Perez, S. K. Proescholdbell, J. C. Sabel, J. Skiba, S. Slavova, K. Stone, J. M. Tharp, T. Wendling, D. Wright, A. M. Zehner, and CDC. 2014. Increases in heroin overdose deaths—28 states, 2010 to 2012. Morbidity and Mortality Weekly Report 63(39):849–854.

Rudd, R. A., P. Seth, F. David, and L. Scholl. 2016. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. Morbidity and Mortality Weekly Report 65(5051):1445–1452.

Rueda, S., S. Mitra, S. Chen, D. Gogolishvili, J. Globerman, L. Chambers, M. Wilson, C. H. Logie, Q. Shi, and S. Morassaei. 2016. Examining the associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: A series of meta-analyses. BMJ Open 6(7):e011453.

Ruhm, C. 2019. Nonopioid overdose death rates rose almost as fast as those involving opioids, 1999–2016. Health Affairs (Millwood) 38(7):1216–1224.

Ryan, J., L. Pagel, K. Smali, S. Artiga, R. Rudowitz, and A. Gates. 2016. Connecting the justice-involved population to Medicaid coverage and care: Findings from three states. Henry J. Kaiser Family Foundation. http://files.kff.org/attachment/Issue-Brief-Connecting-the-Justice-Involved-Population-to-Medicaid-Coverage-and-Care (accessed December 9, 2019).

Safren, S. A., K. H. Mayer, S. S. Ou, M. McCauley, B. Grinsztejn, M. C. Hosseinipour, N. Kumarasamy, T. Gamble, I. Hoffman, D. Celentano, Y. Q. Chen, and M. S. Cohen. 2015. Adherence to early antiretroviral therapy: Results from HPTN 052, a Phase III, multinational randomized trial of ART to prevent HIV-1 sexual transmission in serodiscordant couples. Journal of Acquired Immune Deficiency Syndromes 69(2):234–240.

Saloner, B., Y. Akosa Antwi, J. C. Maclean, and B. Cook. 2018. Access to health insurance and utilization of substance use disorder treatment: Evidence from the Affordable Care Act dependent coverage provision. Health Economics 27(1):50–75.

Samet, J. H., and D. A. Fiellin. 2015. Opioid substitution therapy—time to replace the term. The Lancet 385(9977):1508–1509.

Samet, J. H., M. Botticelli, and M. Bharel. 2018. Methadone in primary care—one small step for Congress, one giant leap for addiction treatment. New England Journal of Medicine 379(1):7–8.

SAMHSA (Substance Abuse and Mental Health Services Administration). 2013. Innovations in addictions treatment: Addiction treatment providers working with integrated primary care services. https://www.integration.samhsa.gov/clinical-practice/13_May_CIHS_Innovations.pdf (accessed December 2, 2019).

SAMHSA. 2015a. Federal guidelines for opioid treatment programs. https://store.samhsa.gov/system/files/pep15-fedguideotp.pdf (accessed December 1, 2019).

SAMHSA. 2015b. Tool 1: Partnership checklist. https://www.integration.samhsa.gov/operationsadministration/OATI_Tool1_Partnership_checklist.pdf (accessed December 2, 2019).

SAMHSA. 2015c. Tool 3: The Administrative Readiness Tool (ART). https://www.integration.samhsa.gov/operations-administration/OATI_Tool3_ART.pdf (accessed December 2, 2019).

SAMHSA. 2015d. Tool 4: COMPASS Primary Health and Behavioral Health. https://www.integration.samhsa.gov/operations-administration/OATI_Tool4_COMPASS.pdf (accessed December 2, 2019).

SAMHSA. 2016. Medication-assisted treatment of opioid use disorder pocket guide. https://store.samhsa.gov/product/Medication-Assisted-Treatment-of-Opioid-Use-Disorder-Pocket-Guide/SMA16-4892PG (accessed January 8, 2020).

SAMHSA. 2017. Apply to increase patient limits. https://www.samhsa.gov/medicationassisted-treatment/buprenorphine-waiver-management/increase-patient-limits (accessed August 20, 2019).

SAMHSA. 2018a. Medicaid coverage of medication-assisted treatment for alcohol and opioid use disorders and of medication for the reversal of opioid overdose. https://store.samhsa.gov/system/files/medicaidfinancingmatreport_0.pdf (accessed October 7, 2019).

SAMHSA. 2018b. ONC and SAMHSA release fact sheets on 42 CFR Part 2: Confidentiality of substance use disorder records. https://www.samhsa.gov/newsroom/pressannouncements/201805020200 (accessed October 15, 2019).

SAMHSA. 2019a. Apply for a practitioner waiver. https://www.samhsa.gov/medicationassisted-treatment/training-materials-resources/apply-for-practitioner-waiver (accessed December 2, 2019).

SAMHSA. 2019b. Fiscal year 2020 grant announcements and awards. https://www.samhsa.gov/grants/grant-announcements-2020 (accessed October 17, 2019).

SAMHSA. 2019c. Medication and counseling treatment. https://www.samhsa.gov/medicationassisted-treatment/treatment#otps (accessed December 9, 2019).

SAMHSA. 2019d. Medication-assisted treatment (MAT) in the criminal justice system: Brief guidance to the states. https://store.samhsa.gov/product/Medication-Assisted-Treatment-MATin-the-Criminal-Justice-System-Brief-Guidance-to-the-States/PEP19-MATBRIEFCJS (accessed December 5, 2019).

SAMHSA. 2019e. Methadone. https://www.samhsa.gov/medication-assisted-treatment/treatment/methadone (accessed September 18, 2019).

SAMHSA. 2019f. Promoting integration of primary and behavioral health care. https://www.samhsa.gov/grants/grant-announcements/sm-20-003 (accessed December 4, 2019).

SAMHSA. 2019g. Qualify for nurse practitioners (NPs) and physician assistants (PAs) waiver. https://www.samhsa.gov/medication-assisted-treatment/training-materials-resources/qualify-np-pa-waivers (accessed August 20, 2019).

SAMHSA. 2019h. State targeted response technical assistance (STR-TA). https://www.samhsa.gov/state-targeted-response-technical-assistance (accessed October 17, 2019).

SAMHSA. 2019i. Use of medication-assisted treatment for opioid use disorder in criminal justice settings. HHS Publication No. PEP19-MATUSECJS. https://store.samhsa.gov/system/files/guide_4-0712_final_-_section_508_compliant.pdf (accessed December 5, 2019).

SAMHSA. 2019j. What is integrated care? https://www.integration.samhsa.gov/about-us/what-is-integrated-care (accessed November 26, 2019).

SAMHSA. 2019k. Workforce. https://www.samhsa.gov/workforce (accessed October 14, 2019).

Sansone, R. A., and L. A. Sansone. 2015. Buprenorphine treatment for narcotic addiction: Not without risks. Innovations in Clinical Neuroscience 12(3–4):32–36.

Sax, P. 2019. The comprehensive infectious disease update: Prevention, diagnosis, treatment. https://idprimarycare.hmscme.com (accessed December 7, 2019).

Sbaraini, A., S. M. Carter, R. W. Evans, and A. Blinkhorn. 2011. How to do a grounded theory study: A worked example of a study of dental practices. BMC Medical Research Methodology 11(1):128.

Schaper, E., H. Padwa, D. Urada, and S. Shoptaw. 2016. Substance use disorder patient privacy and comprehensive care in integrated health care settings. Psychological Services 13(1):105–109.

Schranz, A. J., A. Fleischauer, V. H. Chu, L. T. Wu, and D. L. Rosen. 2018. Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017: A study of statewide discharge data. Annals of Internal Medicine 170(1):31–40.

Sequera, V.-G., S. Valencia, A. L. García-Basteiro, A. Marco, and J. M. Bayas. 2015. Vaccinations in prisons: A shot in the arm for community health. Human Vaccines & Immunotherapeutics 11(11):2615–2626.

Showalter, D. 2018. Federal funding for syringe exchange in the US: Explaining a long-term policy failure. International Journal of Drug Policy 55:95–104.

Silins, E., E. Silins, K. M. Conigrave, E. Silins, K. M. Conigrave, C. Rakvin, E. Silins, K. M. Conigrave, C. Rakvin, and T. Dobbins. 2007. The influence of structured education and clinical experience on the attitudes of medical students towards substance misusers. Drug and Alcohol Review 26(2):191–200.

Simeone, C., B. Shapiro, and P. J. Lum. 2017. Integrated HIV care is associated with improved engagement in treatment in an urban methadone clinic. Addiction Science & Clinical Practice 12(1):19.

Sittambalam, C. D., R. Vij, and R. P. Ferguson. 2014. Buprenorphine outpatient outcomes project: Can Suboxone be a viable outpatient option for heroin addiction? Journal of Community Hospital Internal Medicine Perspectives 4(2):22902.

Sohler, N. L., X. Li, H. V. Kunins, G. Sacajiu, A. Giovanniello, S. Whitley, and C. O. Cunningham. 2010. Home- versus office-based buprenorphine inductions for opioid-dependent patients. Journal of Substance Abuse Treatment 38(2):153–159.

Sood, N., T. Juday, J. Vanderpuye-Orgle, L. Rosenblatt, J. A. Romley, D. Peneva, and D. P. Goldman. 2014. HIV care providers emphasize the importance of the Ryan White program for access to and quality of care. Health Affairs 33(3):394–400.

Soper, R., S. Appajosyula, and C. Deximo. 2018. Decline in buprenorphine/naloxone prescriptions in a state Medicaid population following formulary conversion from Suboxone to Bunavail. Advances in Therapy 35(4):457–466.

Spaulding, A. C., E. J. Anderson, M. A. Khan, C. A. Taborda-Vidarte, and J. A. Phillips. 2017. HIV and HCV in U.S. prisons and jails: The correctional facility as a bellwether over time for the community’s infections. AIDS Review 19(3):134–147.

Springer, S. A., E. Pesanti, J. Hodges, T. Macura, G. Doros, and F. L. Altice. 2004. Effectiveness of antiretroviral therapy among HIV-infected prisoners: Reincarceration and the lack of sustained benefit after release to the community. Clinical Infectious Diseases 38(12):1754–1760.

Springer, S. A., S. Chen, and F. L. Altice. 2010. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: The impact of buprenorphine treatment. Journal of Urban Health 87(4):592–602.

Springer, S. A., A. C. Spaulding, J. P. Meyer, and F. L. Altice. 2011. Public health implications for adequate transitional care for HIV-infected prisoners: Five essential components. Clinical Infectious Diseases 53(5):469–479.

Springer, S. A., J. Qiu, A. S. Saber-Tehrani, and F. L. Altice. 2012. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid-dependent released prisoners. PLoS One 7(5):e38335.

Springer, S. A., A. P. Di, M. M. Azar, R. Barbour, B. E. Biondi, M. Desabrais, T. Lincoln, D. J. Skiest, and F. L. Altice. 2018. Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: Results of a double-blind, placebo-controlled randomized trial. Journal of Acquired Immune Deficiency Syndromes (1999) 78(1):43–53.

Stein, B. D., A. J. Gordon, M. Sorbero, A. W. Dick, J. Schuster, and C. Farmer. 2012. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: Recent service utilization trends in the use of buprenorphine and methadone. Drug and Alcohol Dependence 123(1–3):72–78.

Stein, B. D., M. Sorbero, A. W. Dick, R. L. Pacula, R. M. Burns, and A. J. Gordon. 2016. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. Journal of the American Medical Association 316(11):1211–1212.

Stein, J., M. Hunter, K. Clarkson, L. Rutledge, X. Becerra, P. Weiser, W. Tong, K. Jennings, K. Racine, and A. Moody. 2019. Letter from National Association of Attorneys General. Washington, DC, August 5, 2019.

Steinberg, J. 2014. Advancing behavioral health integration within NCQA recognized patient-centered medical homes. https://www.integration.samhsa.gov/integrated-care-models/Behavioral_Health_Integration_and_the_Patient_Centered_Medical_Home_FINAL.pdf (accessed December 2, 2019).

Stephenson, B. L., D. A. Wohl, C. E. Golin, H. C. Tien, P. Stewart, and A. H. Kaplan. 2005. Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. Public Health Reports 120(1):84–88.

Stone, J., H. Fraser, A. G. Lim, J. G. Walker, Z. Ward, L. MacGregor, A. Trickey, S. Abbott, S. A. Strathdee, and D. Abramovitz. 2018. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: A systematic review and meta-analysis. Lancet Infectious Diseases 18(12):1397–1409.

Strathdee, S. A., E. P. Ricketts, S. Huettner, L. Cornelius, D. Bishai, J. R. Havens, P. Beilenson, C. Rapp, J. J. Lloyd, and C. A. Latkin. 2006. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: Results from a community-based behavioral intervention trial. Drug and Alcohol Dependence 83(3):225–232.

Sullivan, L. E., J. Tetrault, D. Bangalore, and D. A. Fiellin. 2006. Training HIV physicians to prescribe buprenorphine for opioid dependence. Substance Abuse 27(3):13–18.

Sullivan, N. 2012. Enacting spaces of inequality: Placing global/state governance within a Tanzanian hospital. Space and Culture 15(1):57–67.

Syed, S. T., B. S. Gerber, and L. K. Sharp. 2013. Traveling towards disease: Transportation barriers to health care access. Journal of Community Health 38(5):976–993.

Tanaka, S. 2019. Criminal justice interventions: Plumas County naloxone distribution program. Plumas County District Attorney Alternative Sentencing Program.

TARGET (Technical Assistance Resources, Guidance, Education, & Training Center for the Ryan White community). 2019. Integrating buprenorphine treatment for opioid use disorder in HIV primary care. https://nextlevel.targethiv.org/deii/buprenorphine (accessed January 9, 2020).

Teixeira, P. A., A. O. Jordan, N. Zaller, D. Shah, and H. Venters. 2015. Health outcomes for HIV-infected persons released from the New York City jail system with a transitional care-coordination plan. American Journal of Public Health 105(2):351–357.

Teshale, E. H., A. Asher, M. V. Aslam, R. Augustine, E. Duncan, A. Rose-Wood, J. Ward, J. Mermin, K. Owusu-Edusei, and P. M. Dietz. 2019. Estimated cost of comprehensive syringe service program in the United States. PLoS One 14(4):e0216205.

Thomas, C. P., E. Doyle, P. W. Kreiner, C. M. Jones, J. Dubenitz, A. Horan, and B. D. Stein. 2017. Prescribing patterns of buprenorphine waivered physicians. Drug and Alcohol Dependence 181:213–218.

Topp, S. M., J. M. Chipukuma, M. M. Chiko, E. Matongo, C. Bolton-Moore, and S. E. Reid. 2012. Integrating HIV treatment with primary care outpatient services: Opportunities and challenges from a scaled-up model in Zambia. Health Policy and Planning 28(4):347–357.

Tran Smith, B., K. Seaton, C. Andrews, C. M. Grogan, A. Abraham, H. Pollack, P. Friedmann, and K. Humphreys. 2018. Benefit requirements for substance use disorder treatment in state health insurance exchanges. American Journal of Drug and Alcohol Abuse 44(4):426–430.

Tsui, J. I., J. L. Evans, P. J. Lum, J. A. Hahn, and K. Page. 2014. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Internal Medicine 174(12):1974–1981.

UB (State University of New York at Buffalo). 2019. Sharing telemedicine success for HCV, opioid use disorder. http://medicine.buffalo.edu/alumni/classnotes/news.host.html/content/shared/smbs/news/2019/06/talal-telemedicine-program-10085.detail.html (accessed October 16, 2019).

Uchtenhagen, A. 2013. Abstinence versus agonist maintenance treatment: An outdated debate? European Addiction Research 19(6):283–286.

Umbricht-Schneiter, A., D. H. Ginn, K. M. Pabst, and G. E. Bigelow. 1994. Providing medical care to methadone clinic patients: Referral vs. on-site care. American Journal of Public Health 84(2):207–210.

Undem, T. 2010. Consumers and health information technology: A national survey. https://www.chcf.org/wp-content/uploads/2017/12/PDF-ConsumersHealthInfoTechnologyNationalSurvey.pdf (accessed August 23, 2019).

Urahn, S., M. Thompson, K. Huh, A. Boucher, F. McGaffey, M. McKillop, and M. Schif. 2017a. Pharmaceuticals in state prisons: How departments of corrections purchase, use, and monitor prescription drugs. Philadelphia, PA: Pew Charitable Trusts.

Urahn, S., M. Thompson, K. Huh, A. Boucher, F. McGaffey, M. McKillop, and M. Schif. 2017b. Prison health care: Costs and quality: How and why states strive for high-performing systems. Philadelphia, PA: Pew Charitable Trusts.

Urahn, S., M. Thompson, K. Huh, A. Boucher, F. McGaffey, M. McKillop, and M. Schiff. 2018. Jails: Inadvertent health care providers: How county correctional facilities are playing a role in the safety net. Philadelphia, PA: Pew Charitable Trusts.

U.S. Congress, House. 2019. Mainstreaming Addiction Act of 2019. H.R. 2482 to amend section 303(g) of the Controlled Substances Act 116th Congress., 1st Sess. https://www.congress.gov/116/bills/hr2482 (accessed September 30, 2019).

USPSTF (U.S. Preventive Services Task Force). 2019a. Draft recommendation statement: Hepatitis C virus infection in adolescents and adults: Screening. https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/hepatitis-c-screening1 (accessed September 23, 2019).

USPSTF. 2019b. Draft recommendation statement: Illicit drug use, including nonmedical use of prescription drugs: Screening. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementDraft/drug-use-in-adolescents-and-adultsincluding-pregnant-women-screening (accessed September 17, 2019).

Van Boekel, L. C., E. P. Brouwers, J. Van Weeghel, and H. F. Garretsen. 2013. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. Drug and Alcohol Dependence 131(1–2):23–35.

Van Den Berg, C., C. Smit, G. Van Brussel, R. Coutinho, and M. Prins. 2007. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: Evidence from the Amsterdam cohort studies among drug users. Addiction 102(9):1454–1462.

Vestal, C. 2018. Long stigmatized, methadone clinics multiply in some states. https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2018/10/31/long-stigmatized-methadone-clinics-multiply-in-some-states (accessed October 16, 2019).

Vigilant, L. G. 2004. The stigma paradox in methadone maintenance: Naïve and positive consequences of a “treatment punishment” approach to opiate addiction. Humanity & Society 28(4):403–418.

Villano, S. A., K. E. Nelson, D. Vlahov, R. H. Purcell, A. J. Saah, and D. L. Thomas. 1997. Hepatitis A among homosexual men and injection drug users: More evidence for vaccination. Clinical Infectious Diseases 25(3):726–728.

Volkow, N. D., T. R. Frieden, P. S. Hyde, and S. S. Cha. 2014. Medication-assisted therapies—tackling the opioid-overdose epidemic. New England Journal of Medicine 370(22):2063–2066.

Wakeman, S. E., and M. L. Barnett. 2018. Primary care and the opioid-overdose crisis—buprenorphine myths and realities. New England Journal of Medicine 379(1):1–4.

Wakeman, S. E., and P. Friedmann. 2017. Outdated privacy law limits effective substance use disorder treatment: The case against 42 CFR Part 2. Health Affairs, https://www.healthaffairs.org/do/10.1377/hblog20170301.058969/full (accessed August 22, 2019).

Walley, A. Y., D. Farrar, D. M. Cheng, D. P. Alford, and J. H. Samet. 2009. Are opioid dependence and methadone maintenance treatment (MMT) documented in the medical record? A patient safety issue. Journal of General Internal Medicine 24(9):1007–1011.

Wang, E. A., H.-j. Lin, J. A. Aminawung, S. H. Busch, C. Gallagher, K. Maurer, L. Puglisi, S. Shavit, and L. Frisman. 2019. Propensity-matched study of enhanced primary care on contact with the criminal justice system among individuals recently released from prison to New Haven. BMJ Open 9(5):e028097.

Wang, P. S., O. Demler, M. Olfson, H. A. Pincus, K. B. Wells, and R. C. Kessler. 2006. Changing profiles of service sectors used for mental health care in the United States. American Journal of Psychiatry 163(7):1187–1198.

Weber, E., and A. Gupta. 2019. State Medicaid programs should follow the “Medicare model”: Remove prior authorization requirements for buprenorphine and other medications to treat opioid use disorders. Washington, DC: Legal Action Center.

Weems, J. A. 2019. Feasibility and evaluation of a pilot buprenorphine training for medical students. Doctoral dissertation, Harvard Medical School. Boston, MA. https://dash.harvard.edu/handle/1/40620216 (accessed January 9, 2020).

Wen, H., T. F. Borders, and J. R. Cummings. 2019. Trends in buprenorphine prescribing by physician specialty. Health Affairs 38(1):24–28.

Westervelt, E. 2019. County jails struggle with a new role as America’s prime centers for opioid detox. https://www.npr.org/2019/04/24/716398909/county-jails-struggle-with-a-new-role-as-americas-prime-centers-for-opioid-detox (accessed September 16, 2019).

White House. 2018. Ending America’s opioid crisis. https://www.whitehouse.gov/opioids (accessed December 5, 2019).

WHO (World Health Organization). 2004. Proposal for the inclusion of buprenorphine in the WHO model list of essential medicines. Geneva, Switzerland: Department of Mental Health and Substance Abuse, HIV/AIDS Department, World Health Organization.

Williams, A. R., and A. Bisaga. 2016. From AIDS to opioids—how to combat an epidemic. New England Journal of Medicine 375(9):813–815.

Williams, A., E. Nunes, and M. Olfson. 2017. To battle the opioid overdose epidemic, deploy the “cascade of care” model. Health Affairs 10.1377/hblog20170313.059163. https://www.healthaffairs.org/do/10.1377/hblog20170313.059163/full (accessed January 9, 2020).

Williams, A. R., E. V. Nunes, A. Bisaga, F. R. Levin, and M. Olfson. 2019. Development of a cascade of care for responding to the opioid epidemic. American Journal of Drug and Alcohol Abuse 45(1):1–10.

Winkelman, T. N., V. W. Chang, and I. A. Binswanger. 2018. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Network Open 1(3):e180558.

Wurcel, A. G., J. E. Anderson, K. K. Chui, S. Skinner, T. A. Knox, D. R. Snydman, and T. J. Stopka. 2016. Increasing infectious endocarditis admissions among young people who inject drugs. Open Forum Infectious Diseases 3(3):ofw157.

Yang, L. H., L. Y. Wong, M. M. Grivel, and D. S. Hasin. 2017. Stigma and substance use disorders: An international phenomenon. Current Opinion in Psychiatry 30(5):378–388.

Zibbell, J. E., K. Iqbal, R. C. Patel, A. Suryaprasad, K. J. Sanders, L. Moore-Moravian, J. Serrecchia, S. Blankenship, J. W. Ward, and D. Holtzman. 2015. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years—Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. Morbidity and Mortality Weekly Report 64(17):453–458.

Zibbell, J. E., A. K. Asher, R. C. Patel, B. Kupronis, K. Iqbal, J. W. Ward, and D. Holtzman. 2018. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. American Journal of Public Health 108(2):175–181.